AtriCure Financial Statements (ATRC)
|
|
Report date
|
|
|
26.02.2021 |
17.02.2022 |
31.12.2022 |
22.02.2023 |
16.02.2024 |
|
30.10.2024 |
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
206.5 |
274.3 |
330.4 |
330.4 |
399.2 |
|
447.6 |
Operating Income, bln rub |
|
|
-44.2 |
-47.3 |
-42.7 |
-42.7 |
-26.7 |
|
-34.2 |
EBITDA, bln rub |
? |
|
-33.6 |
-36.9 |
-46.2 |
-29.5 |
-8.11 |
|
-12.9 |
Net profit, bln rub |
? |
|
-48.2 |
50.2 |
-46.5 |
-46.5 |
-30.4 |
|
-38.9 |
|
OCF, bln rub |
? |
|
-19.9 |
-13.8 |
|
-22.1 |
4.48 |
|
10.4 |
CAPEX, bln rub |
? |
|
5.26 |
9.75 |
|
16.9 |
42.0 |
|
11.6 |
FCF, bln rub |
? |
|
-25.1 |
-23.5 |
|
-39.0 |
-37.5 |
|
-1.15 |
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
|
0.000 |
0.000 |
|
0.000 |
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
OPEX, bln rub |
|
|
193.5 |
253.2 |
288.6 |
288.6 |
327.1 |
|
366.6 |
Cost of production, bln rub |
|
|
57.2 |
68.5 |
84.4 |
84.4 |
98.9 |
|
115.1 |
R&D, bln rub |
|
|
43.1 |
48.5 |
57.3 |
57.3 |
73.9 |
|
81.3 |
Interest expenses, bln rub |
|
|
4.89 |
4.92 |
0.000 |
4.99 |
6.93 |
|
6.75 |
|
Assets, bln rub |
|
|
714.5 |
615.3 |
585.4 |
585.4 |
613.9 |
|
615.1 |
Net Assets, bln rub |
? |
|
412.4 |
483.8 |
456.8 |
456.8 |
466.2 |
|
465.0 |
Debt, bln rub |
|
|
74.0 |
75.6 |
69.1 |
69.1 |
74.5 |
|
77.1 |
Cash, bln rub |
|
|
244.2 |
119.1 |
121.1 |
121.1 |
137.3 |
|
130.3 |
Net debt, bln rub |
|
|
-170.2 |
-43.4 |
-52.0 |
-52.0 |
-62.8 |
|
-53.2 |
|
Ordinary share price, rub |
|
|
55.7 |
69.5 |
44.4 |
44.4 |
35.7 |
|
33.5 |
Number of ordinary shares, mln |
|
|
42.1 |
45.1 |
42.1 |
45.7 |
46.3 |
|
47.1 |
|
Market cap, bln rub |
|
|
2 345 |
3 133 |
1 870 |
2 030 |
1 653 |
|
1 578 |
EV, bln rub |
? |
|
2 175 |
3 090 |
1 817 |
1 978 |
1 590 |
|
1 525 |
Book value, bln rub |
|
|
49 |
206 |
457 |
183 |
167 |
|
172 |
|
EPS, rub |
? |
|
-1.14 |
1.11 |
-1.10 |
-1.02 |
-0.66 |
|
-0.83 |
FCF/share, rub |
|
|
-0.60 |
-0.52 |
0.00 |
-0.85 |
-0.81 |
|
-0.02 |
BV/share, rub |
|
|
1.17 |
4.57 |
10.8 |
3.99 |
3.61 |
|
3.65 |
|
EBITDA margin, % |
? |
|
-16.3% |
-13.4% |
-14.0% |
-8.93% |
-2.03% |
|
-2.89% |
Net margin, % |
? |
|
-23.3% |
18.3% |
-14.1% |
-14.1% |
-7.62% |
|
-8.70% |
FCF yield, % |
? |
|
-1.07% |
-0.75% |
0.00% |
-1.92% |
-2.27% |
|
-0.07% |
ROE, % |
? |
|
-11.7% |
10.4% |
-10.2% |
-10.2% |
-6.53% |
|
-8.37% |
ROA, % |
? |
|
-6.74% |
8.16% |
-7.94% |
-7.94% |
-4.96% |
|
-6.33% |
|
P/E |
? |
|
-48.7 |
62.4 |
-40.2 |
-43.7 |
-54.3 |
|
-40.5 |
P/FCF |
|
|
-93.3 |
-133.2 |
|
-52.0 |
-44.1 |
|
-1 367 |
P/S |
? |
|
11.4 |
11.4 |
5.66 |
6.14 |
4.14 |
|
3.53 |
P/BV |
? |
|
47.5 |
15.2 |
4.09 |
11.1 |
9.87 |
|
9.18 |
EV/EBITDA |
? |
|
-64.7 |
-83.8 |
-39.3 |
-67.0 |
-196.1 |
|
-117.8 |
Debt/EBITDA |
|
|
5.06 |
1.18 |
1.13 |
1.76 |
7.74 |
|
4.11 |
|
R&D/CAPEX, % |
|
|
819.0% |
497.3% |
|
339.7% |
176.0% |
|
703.4% |
|
CAPEX/Revenue, % |
|
|
2.55% |
3.56% |
0.00% |
5.11% |
10.5% |
|
2.58% |
|
AtriCure shareholders |